Last reviewed 2026-04-22 · How we verify

Nevirapine, FTC, and Tenofovir

Nevirapine, FTC, and Tenofovir is a Antiretroviral combination (NNRTI + NRTI + NtRI) Small molecule drug developed by University of Maryland, Baltimore. It is currently FDA-approved for HIV-1 infection in treatment-naïve patients, HIV-1 infection in treatment-experienced patients (with appropriate resistance testing).

This is a fixed-dose combination of three antiretroviral drugs that work together to inhibit HIV replication through different mechanisms: reverse transcriptase inhibition and nucleotide reverse transcriptase inhibition.

This is a fixed-dose combination of three antiretroviral drugs that inhibit HIV reverse transcriptase and integrase to suppress viral replication. Used for HIV-1 infection (treatment and prevention).

At a glance

Mechanism of action

Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), while FTC (emtricitabine) and tenofovir are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs). Together, they block HIV reverse transcriptase at different binding sites and through different mechanisms, preventing the virus from converting its RNA genome into DNA and integrating into host cells. This triple-drug combination approach reduces the likelihood of resistance development.

Approved indications

• HIV-1 infection in treatment-naïve patients
• HIV-1 infection in treatment-experienced patients (with appropriate resistance testing)

Common side effects

• Rash (nevirapine-related)
• Hepatotoxicity
• Nausea
• Diarrhea
• Headache
• Renal dysfunction (tenofovir-related)
• Lactic acidosis

Key clinical trials

• Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
• A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
• Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
• Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
• Research on the Psychological Status of Patients With HIV-1 Infection
• Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen (PHASE2, PHASE3)
• A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Nevirapine, FTC, and Tenofovir CI brief — competitive landscape report
• Nevirapine, FTC, and Tenofovir updates RSS · CI watch RSS
• University of Maryland, Baltimore portfolio CI

Frequently asked questions about Nevirapine, FTC, and Tenofovir

Related

• Drug class: All Antiretroviral combination (NNRTI + NRTI + NtRI) drugs
• Target: All drugs targeting HIV reverse transcriptase, HIV integrase
• Manufacturer: University of Maryland, Baltimore — full pipeline
• Therapeutic area: All drugs in Infectious Disease / Virology
• Indication: Drugs for HIV-1 infection in treatment-naïve patients
• Indication: Drugs for HIV-1 infection in treatment-experienced patients (with appropriate resistance testing)
• Compare: Nevirapine, FTC, and Tenofovir vs similar drugs
• Pricing: Nevirapine, FTC, and Tenofovir cost, discount & access